Evidence map›Paper›PMID 29220360›Full record

ArticlePloS one2017

Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice.

Sabina Eigenbrod, Petra Frick, Uwe Bertsch, Gerda Mitteregger-Kretzschmar, Janina Mielke, Marko Maringer, Niklas Piening, Alexander Hepp, Nathalie Daude, Otto Windl and 6 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. N-Terminal Regions of Prion Protein: Functions and Roles in Prion Diseases.International journal of molecular sciences · 2020
    Review
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Sabina EigenbrodCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Petra FrickCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Uwe BertschCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Gerda Mitteregger-KretzschmarCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Janina MielkeCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Marko MaringerCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Niklas PieningCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Alexander HeppCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Nathalie DaudeCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.
Otto WindlCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Johannes LevinCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Armin GieseCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
Vignesh SakthiveluDepartment of Metabolic Biochemistry/Neurobiochemistry, Adolf Butenandt Institute, Ludwig Maximilians University, Munich, Germany.
Jörg TatzeltDepartment of Metabolic Biochemistry/Neurobiochemistry, Adolf Butenandt Institute, Ludwig Maximilians University, Munich, Germany.
Hans KretzschmarCenter for Neuropathology and Prion Research, Ludwig Maximilians University, Munich, Germany.
David WestawayCentre for Prions and Protein Folding Diseases, University of Alberta, Edmonton, Alberta, Canada.ORCID http://orcid.org/0000-0003-1928-4616
Ludwig-Maximilians-Universität München · DEUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prion diseases have been linked to impaired copper homeostasis and copper induced-oxidative damage to the brain. Divalent metal ions, such as Cu2+ and Zn2+, bind to cellular prion protein (PrPC) at octapeptide repeat (OR) and non-OR sites within the N-terminal half of the protein but information on the impact of such binding on conversion to the misfolded isoform often derives from studies using either OR and non-OR peptides or bacterially-expressed recombinant PrP. Here we created new transgenic mouse lines expressing PrP with disrupted copper binding sites within all four histidine-containing OR's (sites 1-4, H60G, H68G, H76G, H84G, "TetraH>G" allele) or at site 5 (composed of residues His-95 and His-110; "H95G" allele) and monitored the formation of misfolded PrP in vivo. Novel transgenic mice expressing PrP(TetraH>G) at levels comparable to wild-type (wt) controls were susceptible to mouse-adapted scrapie strain RML but showed significantly prolonged incubation times. In contrast, amino acid replacement at residue 95 accelerated disease progression in corresponding PrP(H95G) mice. Neuropathological lesions in terminally ill transgenic mice were similar to scrapie-infected wt controls, but less severe. The pattern of PrPSc deposition, however, was not synaptic as seen in wt animals, but instead dense globular plaque-like accumulations of PrPSc in TgPrP(TetraH>G) mice and diffuse PrPSc deposition in (TgPrP(H95G) mice), were observed throughout all brain sections. We conclude that OR and site 5 histidine substitutions have divergent phenotypic impacts and that cis interactions between the OR region and the site 5 region modulate pathogenic outcomes by affecting the PrP globular domain.

Indexed as

AnimalsHistidineMiceMice, TransgenicPrion ProteinsScrapieHistidinePrion Proteins

Identifiers

PMID29220360
PMCPMC5722314
OpenAlexW2775683821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.